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Key messages
 ► Significant brain pathology and cognitive impair-
ment has been consistently demonstrated patients 
with chronic obstructive pulmonary disease (COPD), 
but it is not clear how best to detect and measure 
these brain changes. Current MR analysis requires 
complex data processing and expertise to interpret
 ► A simple, easy to learn visual rating scale may be 
able to detect significant brain pathology in COPD.
 ► We used a simple, validated visual analogue grading 
technique to assess the degree of regional atrophy 
in multiple brain regions from cerebral MR images 
in patients with COPD. It was simple to learn and re-
peatable and shows patients with COPD had signifi-
cantly greater frontal atrophy than control subjects.
AbstrAct
Introduction Widespread white matter damage and 
cognitive impairment have been demonstrated in chronic 
obstructive pulmonary disease (COPD). However, it remains 
unclear if brain atrophy is a global phenomenon or if 
specific subregions are differentially affected. The aims 
of this study are, first, to test a simple, validated visual 
analogue grading technique. Second, we hypothesised 
that frontal regions of the brains of patients with COPD 
will show greater signs of atrophy compared with control 
subjects. Third, any localised regions of atrophy would 
correlate with components of cognitive performance. 
Finally, the severity of cerebral atrophy would be 
associated with measures of respiratory disease severity.
Methods We used a simple, validated visual analogue 
grading technique to assess the degree of regional 
atrophy in multiple brain regions from cerebral MR 
images in patients with stable non-hypoxaemic COPD 
(n=25) and age-matched control subjects (n=25). We 
also explored correlations between regional brain atrophy 
with demographics, cognitive performance measures 
and disease severity. Measures of cognitive performance 
focused on executive function, working memory, verbal 
memory, overall memory and processing speed. Measures 
of disease severity include lung function, gas exchange, 
health status and breathlessness questionnaires.
results The visual grading scale found that patients 
with COPD had significantly greater frontal atrophy than 
control subjects (p=0.02), independent of smoking history, 
comorbid depression or anxiety. Cognitive function was 
significantly worse in the COPD group for executive 
function (p<0.001), working memory (p=0.02), verbal 
memory (p=0.03) and processing speed (p=0.001). 
Group differences in atrophy did not appear to account 
for differences in cognitive function. We were unable to 
identify meaningful correlations between regional atrophy 
and disease severity or cognitive function.
conclusion Further work is needed to identify causative 
mechanisms behind unexplained structural brain changes 
in COPD.
IntroductIon
It is well established that patients with chronic 
obstructive pulmonary disease (COPD) 
have multiple comorbidities, such as heart 
disease, stroke, skeletal muscle wasting and 
depression.1 2 These systemic effects are 
not explained by shared risk factors alone, 
such as cigarette smoking, hypertension of 
hypoxaemia, leading to the hypothesis of a 
‘COPD-specific’ risk for comorbidity.3 The 
presence of comorbidities in COPD is associ-
ated with significantly worse patient outcomes 
such as increased hospitalisations, impaired 
functional capacity, decreased quality of life 
and mortality.3 Therefore, characterising and 
understanding these comorbidities is essen-
tial to optimising the management of each 
individual patient.
Previous studies have shown that up to 77% 
of patients with hypoxaemia with COPD have 
cognitive impairment indicative of cerebral 
dysfunction.4 This has also been demonstrated 
in non-hypoxaemic patients with COPD.5 
There is also evidence that cognitive impair-
ment in COPD is associated with reduced 
ability to carry out basic and instrumental 
activities of daily living6 7 and poor medication 
adherence.8 Combined, these factors are likely 
to contribute to increased exacerbations and 
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increased length of hospital stay9 and, possibly, increased 
mortality.10 The identification of COPD as a risk factor 
for accelerated cognitive dysfunction11 presents clinicians 
and researchers with a potential target for interventions 
to prevent or delay cognitive impairment.
People with COPD have been found to perform poorly 
across a wide spectrum of cognitive areas. The most 
frequent and severely affected cognitive domains appear 
to be those related to executive function, attention and 
memory.5 Motor function and processing speed are also 
likely to be negatively impacted on by COPD.12 We may 
therefore expect specific regions of the brain, thought to 
be functionally linked to these cognitive domains, to be 
at risk of damage in patients with COPD, for example, 
executive function and frontal lobes.
Previous analysis of global microstructural changes in 
this population of stable, non-hypoxaemic COPD MR 
diffusion tensor imaging showed extensive reduction in 
white matter integrity, but no difference in the overall 
volume of grey or white matter, suggesting generalised 
cerebral atrophy, was unlikely.13 Two small studies in 
patients with hypoxaemia with COPD found evidence of 
frontal lobe hypoperfusion with the authors concluding 
that anterior cerebral hypoperfusion could herald fron-
tal-type cognitive decline with the worsening of the hypox-
aemia.14 15 Hippocampal atrophy has also been identified 
in COPD16 in addition to localised grey matter (GM) 
loss.17 18 However, these studies are limited, as they require 
complex data processing and statistical techniques, which 
do not always adequately adjust for multiple comparisons.
In this study, we test a simple, validated visual MRI 
rating scale to analyse multiple brain regions of stable, 
non-hypoxaemic patients with COPD and age-matched 
control subjects. We aimed to identify areas of regional 
brain atrophy, we sought associations between regional 
brain atrophy and cognitive function before looking at 
whether any patient characteristics could account for 
particular regions of atrophy.
There is ongoing debate concerning the neuronal 
pathways and supplementary cortical and subcortical 
brain regions involved in cognitive functioning. We used 
associations more widely accepted to form our hypoth-
eses. The relationship between executive function and 
the frontal lobe19 and that between memory and the 
hippocampus20 are examples. We aimed to test a simple, 
validated visual analogue grading technique in this study. 
We hypothesised that, first, the frontal regions of the 
brains of patients with COPD will show greater signs of 
atrophy compared with control subjects. Second, any 
localised regions of atrophy would correlate with compo-
nents of cognitive performance. Finally, the severity of 




This study was carried out as analysis of data collected from 
a prospective case–control study, titled ‘Brain structure 
and function in chronic obstructive pulmonary disease—a 
multimodal cranial magnetic resonance imaging study’.13 
Twenty-five patients with stable, non-hypoxaemic COPD 
(n=25) were recruited from outpatient respiratory clinics 
of two university teaching hospitals (St George’s Hospital 
and Royal Brompton Hospital) between 2010 and 2011. 
Patients were non-hypoxaemic (PaO2>7.3 kPa)
21 and had 
no exacerbations in the preceding 8 weeks. Recruitment 
of an age-matched control group (n=25) from the local 
community took place through local press advertise-
ments. All subjects were required to have at least primary 
school education or equivalent and be competent in 
English in order to complete neuropsychological testing. 
Control subjects with significant respiratory or cognitive 
difficulties were excluded. Exclusion criteria were other-
wise the same for both groups and included other causes 
of cognitive impairment (overt psychiatric illnesses, 
drugs known to cause sedation or cognitive impairment, 
diagnosis of dementia, current or past alcohol or drug 
abuse), breathlessness attributed to heart disease or 
left ventricular dysfunction, neurologic disease, active 
tumours, vascular complications of diabetes, diagnosis of 
obstructive sleep apnoea, visual and hearing disturbances 
and hepatic failure.
Image acquisition
Whole-brain T1-weighted MRI was performed on all 
patients and controls using a Philips 3T Achieva dual TX 
scanner (with a 32-channel head coil).
Image analysis
Technique
The T1-weighted MRI images were analysed in the 
coronal plane by a rater blinded to the clinical condi-
tion of each subject. A validated visual analogue MRI 
grading technique was used to assess the degree of 
atrophy in multiple brain regions.22 Fifteen brain 
regions were rated bilaterally using a 5-point Likert-
type scale: 0=no atrophy; 1=borderline appearances, 
not necessarily abnormal; 2=definitive signs of atrophy; 
3=severe atrophy, with preservation of structure to 
a degree; 4=very severe atrophy, GM not discern-
ible in cortical structures. Each structure was located 
within one of four slices, chosen using defined land-
marks (from anterior to posterior), namely: slice 1=at 
the level where the internal capsule can first be seen; 
slice 2=at the level of the intralimbic gyrus’ medial 
opening; slice 3=at the level of the lateral geniculate 
nucleus; slice 4=the level where the fornix can be seen 
in continuity beside the pulvinar nucleus. In slice 1, 
the anterior temporal lobe, basal ganglia, orbitofrontal 
cortex, dorsolateral frontal cortex and anterior cingu-
late were rated; in slice 2, the anterior hippocampus, 
entorhinal cortex, perirhinal cortex, anterior fusiform 
gyrus, lateral temporal lobe and insula; in slice 3, the 
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Figure 1 Slice 1 in the right hemispheres of two different 
subject brains. The white line highlights the dorsalfrontal 
lobe. This region would be rated as 0 for brain A (not 
atrophic) and 2 for brain B (signs of atrophy).
Figure 2 Slice 2 in the left hemispheres of two different 
subject brains. The white line highlights the lateral temporal 
lobe. This region would be rated as 0 for brain A (not 
atrophic) and 2 for brain B (signs of atrophy).
4, the posterior hippocampus and Brodmann area 37. 
Figures 1 and 2 demonstrate rating examples in slice 1 
and slice 2 for different subject brains.
Rater training
The rater (CCS) was trained using a subset of the MRI 
scans collected for this study, alongside images provided 
in the original paper describing the technique. The same 
scan set was independently rated by an experienced rater 
(CP). An iterative training process was used initially, 
followed by rerating of 10 scans to give a measure of intr-
arater reliability (measured using Cohen’s kappa coeffi-
cient).
health assessments
All participants’ demographic and medical histories 
were collected through interview and medical records. 
Age, gender, educational level (based on General Certif-
icate of Secondary Education, A level, diploma, degree 
or other levels of qualification) and pack-years were 
recorded. The following areas were also explored:
 ► Comorbidity: Charlson Comorbidity Index (CCI).23
 ► Cerebrovascular risk: modified Framingham’s Stroke 
Risk Profile (FSRP) (ECG-defined left ventricular 
hypertrophy omitted).24
 ► Mood: the Hospital Anxiety and Depression (HAD) 
questionnaire.25
With regard to the above three scoring methods, 
the higher the number obtained, the worse outcome 
predicted.
Additionally, the following were captured for the COPD 
group only, to define functionality and disease severity:
 ► Forced expiratory volume in 1 s (FEV1).
 ► Forced vital capacity.
 ► PaO2 and PaCO2 using arterialised earlobe capillary 
blood gases (COPD subjects only).
 ► St George’s Respiratory Questionnaire (SGRQ)—a 
50-item questionnaire. A score of 100 indicates the 
worst possible health status and 0 indicates the best 
possible health status.
 ► Medical Research Council Dyspnoea Scale was used 
to measure patients’ perceived respiratory disability, 
based on their degree of breathlessness.
neuropsychological tests
In addition to the Mini-Mental State Examination 
(MMSE) cognitive screening tool,26 a comprehensive 
neuropsychological battery was used. Executive func-
tion was tested using verbal fluency and trail making 
from the Delis-Kaplan system27; working memory 
using letter-number sequencing and spatial span from 
Wechsler Adult Intelligence Scale28; visual memory using 
Rey Complex29 Figure-Immediate (3 min) and Delayed 
Recall (30 min) and Recognition; verbal memory using 
Word Lists-List Learning, Word Lists Delayed Recall 
(30 min) and recognition from Wechsler Memory 
Scale,30 and processing speed using the digit symbol 
and symbol search from Wechsler Adult Intelligence 
Scale. Testing was carried out in a quiet room to ensure 
data collection uniformity and in a fixed sequence to 
avoid responses to self-complete questionnaires being 
influenced by subsequent tests. Age-standardised scores 
were then calculated with reference to normative popu-
lation samples.
Age-standardised cognitive scores were generated 
with reference to normative population samples.27–30 
These scores are in the range (mean±SD) of 1–20 (10±3) 
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Table 1 Demographic characteristics and cognitive function of the control group and COPD group
Characteristic Control subjects (n=25) Patients with COPD (n=25) P values
Age (years) 65.32±7.85 67.84±8.16 0.27
Gender (% female) 58.30 41.70 0.40
Education (% of each group) 
  None 16 52 0.03*
  Other 0 8
  GCSE 32 20
  A level 20 8
  Diploma 8 8
  Degree 24 4
Cigarette pack-years 4.16±9.71 58.33±23.80 <0.001*
Charlson Comorbidity Index 
  0 23 0 <0.001*
  1 2 15
  2 0 6
  ≥3 0 4
MMSE 29.28±0.84 28.08±1.66 0.07
FSRP 6.08±3.13 6.96±4.02 0.39
HAD scale 6.76±5.00 12.05±8.16 0.009*
Executive function 12.29±2.57 9.63±2.21 <0.001*
Working memory 11.02±2.48 9.38±2.28 0.02*
Processing speed 11.54±2.24 9.22±2.55 0.001*
Memory (all) 10.93±3.00 9.33±2.71 0.05
Visual memory 10.74±4.57 9.12±4.72 0.22
Verbal memory 11.12±2.74 9.54±2.06 0.03*
Data are presented as mean±SD except where indicated otherwise. P values were obtained using independent samples t-test/Pearson’s χ2 
test depending on normality of distribution.
*Statistically significant result.
COPD, chronic obstructive pulmonary disease; FSRP, Framingham’s Stroke Risk Profile; GCSE, General Certificate of Secondary Education; 
HAD, Hospital Anxiety and Depression; MMSE, Mini-Mental State Examination.
statistical analysis plan
Data were analysed using IBM SPSS version 23. Histo-
grams were plotted for each variable to visually check 
for normality of distribution. Data for demographic 
characteristics, baseline cognitive function and regional 
atrophy were assessed for group differences using an 
independent samples t-test, if normally distributed, or 
Pearson’s χ2 test, if non-normally distributed. Differences 
were deemed significant at p<0.05. Group differences 
in regional atrophy were also analysed after controlling 
for CCI, pack-years and HAD scores, using a gener-
alised linear model multivariate analysis. A bivariate 
correlation was performed in the whole group (COPD 
and controls) and COPD group to test for associations 
between regional atrophy and cognitive function (Pear-
son’s correlation coefficient for normally distributed data 
and Spearman’s rank-order correlation for non-normally 
distributed data). As an exploratory analysis, associations 
between disease severity and regional atrophy were also 
assessed in this way.
results
demographics
Demographic characteristics for the control and COPD 
groups are displayed in table 1. The groups were well 
matched on age, sex, FSRP and MMSE score. As antici-
pated, COPD subjects had a significantly greater number 
of pack-years (4.16 vs 58.33), they were also significantly 
more anxious, depressed and with lower levels of educa-




The weighted kappa coefficient at the start of the training 
process was 0.66 (p<0.001), demonstrating significant 
agreement between the two raters and comparing well 
to the overall inter-rater kappa value of 0.71 (p<0.05) 
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Table 2 Bilaterally summed composite scores for regional atrophy in the control and COPD groups (presented as mean±SD)
Control subjects 
(n=25)
Patients with COPD 
(n=25) P values Corrected p values*
Frontal 5.08±2.68 7.32±3.26 0.01† 0.02†
Temporal 5.76±3.27 7.72±4.77 0.10 0.06
Hippocampal 4.60±1.89 5.24±3.06 0.38 0.05
*Generalised linear model multivariate analysis controlling for group differences in Charlson Comorbidity Index, pack-years and Hospital 
Anxiety and Depression (HAD) scores.
†Statistically significant result.
COPD, chronic obstructive pulmonary disease.
Table 3 Regions included in composite groups
Group Regions











From the ten rerated scans, 300 values were obtained. 
Raw percentage agreement was 77.7% and Cohen’s kappa 
coefficient was 0.66 (p<0.001). Again, this compares 
well to the reported intrarater kappa coefficient of 0.75 
(p<0.05) from the original rating scale paper, indicating 
good intrarater agreement.
regional atrophy
Table 2 shows the bilaterally summed composite scores 
for regional atrophy in the two groups. Grouping the 
scores from anatomically and functionally related regions 
formed the composite scores, as demonstrated in table 3. 
Left and right hemisphere scores were summed to give 
overall bilateral scores and the mean of this value was 
generated. As per a priori hypothesis, frontal regions of 
the patients with COPD were more atrophic than those 
of the control group (p=0.01). This difference in frontal 
atrophy remained significant after controlling for CCI, 
pack-years and HAD scores. There was, however, no 
difference in temporal or hippocampal atrophy between 
the two groups. After statistical correction, hippocampal 
atrophy did not meet significance.
cognitive function
Neuropsychological test scores significantly worse in the 
COPD group compared with controls for executive func-
tion (p<0.001), working memory (p=0.02), processing 
speed (p<0.001) and verbal memory (p=0.03), but mean 
scores for both groups were not in the clinically impaired 
range (table 1). There was no significant difference in 
visual memory (p=0.22) between the two groups. Overall 
difference in memory function (average of visual, verbal 
and working memory performance) did not reach statis-
tical significance (p=0.05).
See online supplementary materials for further descrip-
tion of neuropsychological measures (online supplemen-
tary table 1 and online supplementary figures 1–5)
disease severity within the coPd group
Measures of disease severity for the patients with COPD 
(table 4) demonstrated no significant hypoxaemia or 
hypercapnia. The mean age was 67.8 years and 41% were 
female. Health status was moderately impaired (SGRQ 
51.65). Airway obstruction (FEV1) was moderate (52.51% 
of predicted value).
correlations between regional atrophy and cognitive function
Scores for regional atrophy did not significantly corre-
late with cognitive function in the COPD group. There 
was a large amount of scatter around the regression line 
when the association between frontal atrophy and exec-
utive function was plotted for the COPD and control 
groups. On exploration of the whole group (COPD 
group and control group together) associations between 
verbal memory and atrophy within the temporal (r=0.30, 
p=0.03) and hippocampal (r=−0.33, p=0.02) regions were 
found. However, after correction for multiple compari-
sons using Bonferroni method (p=0.002), these associa-
tions were not significant.
disease severity and regional atrophy
No correlations between regional atrophy in the COPD 
group and selected measures of disease severity within 
this group (PaO2, FEV1 % predicted and SGRQ) were 
found.
dIscussIon
This study set out to use a simple visual MR rating scale22 
in the assessment of regional cerebral atrophy in patients 








pen Resp Res: first published as 10.1136/bmjresp-2018-000310 on 26 November 2018. Downloaded from 
6 Savage CC, et al. BMJ Open Resp Res 2018;5:e000310. doi:10.1136/bmjresp-2018-000310
Open access
Table 4 Clinical, functional and symptomatic measures of the COPD group
Mean±SD Median IQR
FEV1% predicted (n=23) 52.51±20.96 48.00 31.60
6mwd (m) (n=14) 423.25±55.41 432.00 73.13
PaO2 (kPa) (n=24) 10.72±2.07 10.60 2.15
PaCO2 (kPa) (n=24) 5.09±0.47 5.01 0.67
MRC dyspnoea scorenp (n=21) – 2 1
SGRQ (n=22) 51.65±19.98 49.66 30.33
6mwd, 6 min walking distance; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; MRC, Medical 
Research Council; np, non-parametric; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in arterial 
blood; SGRQ, St George’s Respiratory Questionnaire.
rating scale was simple to learn and repeatable between 
raters. It demonstrated significant atrophy in the frontal 
regions of non-hypoxaemic patients with COPD with 
moderate airflow obstruction and health status impair-
ment (p=0.01). There was no difference between the 
two groups in the degree of hippocampal or temporal 
atrophy. This population of patients with COPD had 
worse average cognitive function than controls but no 
significant correlations were found between regional 
atrophy and cognitive function or measures of disease 
severity.
The significant frontal atrophy demonstrated by visual 
rating in these data confirms findings from smaller single-
photon emission computerised tomography (SPECT) 
cerebral perfusion studies in patients with hypoxaemic 
COPD suggesting frontal hypoperfusion.14 15 The frontal 
atrophy demonstrated in this study is consistent with 
the frontal-type cognitive decline thought to occur in 
patients with COPD.9
In contrast to previous studies that have demonstrated 
reduced hippocampal volume in patients with COPD,16 
no significant hippocampal atrophy was found in this 
study. Our findings are also not concordant with recent 
evidence for a correlation between hippocampal volume 
and hypoxaemia.16
Limitations of this study may, in part, account for the 
lack of significant association between regional atrophy, 
cognitive function and disease measures. It is possible that 
the relatively small participant sample size hindered our 
ability to form important potential correlations. However 
the sample size is similar to other imaging studies designed 
to identify meaningful differences in brain pathology in 
a well-characterised population sample such as in this 
study. Age and education are known to predict cognition, 
while the COPD and controls were matched for age in 
this study, differences in educational attainment between 
COPD and control groups were controlled for statisti-
cally. This approach was adopted given the pragmatic 
considerations required to prospectively recruit educa-
tion matched control subjects.
In addition, results obtained from analysing MRI scans 
without using volumetric measurement can only provide 
an estimate for the difference in atrophy between these 
two groups. Clear descriptions are provided in the paper 
in which the technique used in this study was devised.22 
However, there is still the potential for misratings as a 
consequence of structural variation between brains and 
subjectivity of raters. Moreover, the scale suggested for 
use with this technique is relatively narrow, probably 
because it was originally developed for assessing different 
forms of neurodegeneration. This narrow scale makes it 
more difficult to distinguish subtle structural changes, 
which are more likely to be found in patients with COPD.
This study confirms that using a simple visual rating 
scale is effective for investigating atrophy in the brains of 
patients with COPD, advocating its use in future studies. 
The validated technique used in this study was chosen 
as it was inexpensive and specialist equipment was not 
required. The findings of this study have implications for 
our understanding of structural damage in the brains of 
patients with COPD, supporting a possible frontal atrophy 
and executive pattern cognitive impairment. Like many 
of the studies of brain pathology and cognitive function 
in COPD, consistent associations between demographic 
and disease severity are seldom identified. There are 
a number of possible explanations for this. First, the 
principle of ‘cognitive reserve’—the recognition that 
cross-sectional studies are unable to capture cognitive 
decline over time, in particular those of premorbidly 
‘high-normal’ cognition who remain cognitively intact at 
time of assessment but who nevertheless may have under-
gone significant cognitive decline. Second, our traditional 
measures of disease severity have historically focused on 
lung physiology such as FEV1. It is now appreciated that 
they do not reflect the multisystem nature of COPD and 
are not thought to be directly involved in the pathophys-
iology of comorbidity in COPD. Systemic inflammation, 
accelerated ageing, autonomic dysfunction and genetic 
susceptibility have all been considered as possible mecha-
nisms of increased comorbidity such as cognitive impair-
ment and warrant further investigation.32
This was a preliminary study that warrants replicating 
in a larger sample using patients with a wider range in 
severity of COPD. Doing so will improve our under-
standing of to what extent hypoxaemia plays a role in 
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identifying relationships between regions of atrophy and 
cognitive dysfunction.
conclusIons
It is possible to use simple visual rating scale to assess 
regional atrophy in COPD. This technique shows evidence 
of frontal cerebral atrophy in patients with stable, non-hy-
poxaemic COPD independent of comorbidity, smoking 
and mood. These morphological changes may contribute 
to the cognitive impairment displayed in this population; 
however, this study did not find significant correlations 
between the degree of brain atrophy and cognitive func-
tioning or disease severity. Further investigations with a 
larger sample size are needed to explore these impor-
tant potential associations. At this stage, the mechanism 
behind regional atrophy in the brains of patients with 
COPD is unclear.
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